Capital Research Global Investors Has $151.39 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Capital Research Global Investors lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,547,287 shares of the biotechnology company’s stock after buying an additional 9,691 shares during the period. Capital Research Global Investors owned about 1.33% of BioMarin Pharmaceutical worth $151,385,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Havemeyer Place LP acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth $1,743,000. Pinebridge Investments LLC acquired a new stake in BioMarin Pharmaceutical during the fourth quarter valued at $568,000. Parallel Advisors LLC boosted its position in BioMarin Pharmaceutical by 71.7% during the fourth quarter. Parallel Advisors LLC now owns 1,320 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 551 shares during the last quarter. Continuum Advisory LLC acquired a new stake in BioMarin Pharmaceutical during the fourth quarter valued at $6,027,000. Finally, Sivia Capital Partners LLC boosted its position in BioMarin Pharmaceutical by 79.8% during the fourth quarter. Sivia Capital Partners LLC now owns 13,488 shares of the biotechnology company’s stock valued at $802,000 after purchasing an additional 5,986 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Activity

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the transaction, the executive vice president directly owned 79,953 shares in the company, valued at $4,833,958.38. This trade represents a 17.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregory R. Friberg sold 3,281 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $53.85, for a total value of $176,681.85. Following the transaction, the executive vice president owned 51,818 shares in the company, valued at approximately $2,790,399.30. This trade represents a 5.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN opened at $56.55 on Tuesday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $66.28. The stock’s 50-day moving average is $54.29 and its two-hundred day moving average is $56.36. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. The firm has a market cap of $10.93 billion, a P/E ratio of 41.28, a price-to-earnings-growth ratio of 0.43 and a beta of 0.25.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday. Sanford C. Bernstein reduced their price objective on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Truist Financial raised BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. Citigroup assumed coverage on BioMarin Pharmaceutical in a research report on Tuesday, May 19th. They set a “buy” rating and a $75.00 price objective for the company. Finally, HC Wainwright reduced their price objective on BioMarin Pharmaceutical from $55.00 to $50.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $88.67.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.